


PF-06305591

Cat. No.:	HY-114301		
CAS No.:	1449473-97-5		
Molecular Formula:	C ₁₅ H ₂₂ N ₄ O		
Molecular Weight:	274.36		
Target:	Sodium Channel		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 140 mg/mL (510.28 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.6448 mL	18.2242 mL	36.4485 mL
		5 mM	0.7290 mL	3.6448 mL	7.2897 mL
		10 mM	0.3645 mL	1.8224 mL	3.6448 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.11 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.11 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.11 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	PF-06305591 is a potent and highly selective voltage gated sodium channel Na _v 1.8 blocker, with an IC ₅₀ of 15 nM. An excellent preclinical in vitro ADME and safety profile ^[1] .
IC₅₀ & Target	Na _v 1.8 15 nM (IC ₅₀)
In Vitro	PF-06305591 (compound 9) has a highly attractive profile with respect to Na _v selectivity, hERG activity, passive permeability and in vitro metabolic stability ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PF-06305591 (compound 9) has good rat bioavailability. PF-06305591 offers the possibility of investigating higher IC₅₀ multiples of Nav1.8 blockade in the clinic, and therefore a more thorough evaluation of the role of Nav1.8 in the treatment of pain^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Brown AD, et al. The discovery and optimization of benzimidazoles as selective Nav1.8 blockers for the treatment of pain. Bioorg Med Chem. 2019 Jan 1;27(1):230-239.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA